

Cont
A2

44. The method of claims 18 or 28, wherein the mixing is adjusted to a lower intensity rather than completely stopped.

REMARKS

Applicant has amended the instant specification to correct the Blockmans reference page numbering from 143-1556 to 143-156. As this correction is inherent to the reference itself, Applicant contends that it does not represent new matter.

Applicant has canceled claims 1-17 and added new claims 18-44. Claims 18-44 are now pending in this case. Applicant has added claims 18-44 for the purpose of converting claims 1-17 to a format acceptable by the Office and to identify further inventions as supported by the instant specification. Applicant provides below a table indicating support in the specification for claims 18-44.

Claim(s)	Location of Specification Support
18	original claim 1; p. 4 lines 3-11
19	original claim 2; p.6 lines 6-9
20	p. 6 lines 14-17
21	original claim 3; p. 4 lines 5-7
22	original claim 4; p. 4 lines 5-7
23	original claim 4; p. 3 lines 25-31
24	original claim 5; p. 4 lines 12-13
25	original claims 6 and 7; p. 7 lines 1-6
26	original claim 8; p. 7 line 32 to p. 8 line 2
27	original claim 9; p. 4 lines 22-25; Figures 1a-1e
28	original claim 10; p. 7 lines 9-12
29	original claim 2; p.6 lines 6-9
30	p. 6 lines 14-17
31	original claim 3; p. 4 lines 5-7
32	original claim 4; p. 4 lines 5-7
33	original claim 4; p. 3 lines 25-31
34	original claim 5; p. 4 lines 12-13
35	original claims 6 and 7; p. 7 lines 1-6
36	original claim 8; p. 7 line 32 to p. 8 line 2
37	original claim 9; p. 4 lines 22-25; Figures 1a-1e
38	original claim 11; p. 7 lines 27-31
39	original claim 17; p. 7 lines 27-31

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

Claim(s)	Location of Specification Support
40	original claim 12; Figures 1-4
41	original claim 13; p. 4 lines 12-13
42	original claim 14; p.8 lines 4-9
43	original claim 15; p. 1 lines 11-16; p.8 lines 4-9
44	original claim 16; p. 5 lines 29-37


As support for claims 18-44 may be found in the instant specification, Applicant asserts that these claims do not constitute new matter.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 15, 2001

By: 
Carol P. Einaudi
Reg. No. 32,220

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

APPENDIX TO PRELIMINARY AMENDMENT OF MARCH 15, 2001

Amendments to the Specification

Induction of macroaggregate formation is possible on use of various activators (Fig. 1). Such activators, such as, for example, ristocetin, collagen, ADP or epinephrine, are sufficiently well known to the person skilled in the area of platelet aggregation. A summary of the mode of functioning of various activators and their receptors is to be found, for example, in Blockmans D. et al. , Blood Review, 9, 1995, 143-[1556] 156. The reaction kinetics of the formation of macroaggregates through Brownian diffusion vary widely for different activators. On the one hand, the frequency of collisions of microaggregates with other microaggregates or single platelets is crucial for macroaggregate formation. On the other hand, it is important that a collision is "successful", a part being played in turn by the state of activation, the charge condition, the size and number of the pseudopodia and many other parameters. Since the progress of activation brought about by the activators, also called agonists hereinafter, varies widely, it is understandable why in particular the result of macroaggregate formation varies widely, after stopping the stirrer, with the various agonists. The state or activation at the instant when the stirring is stopped is certainly an important parameter for the extent of the reaction proceeding thereafter.